Sudarshan Pharma to Acquire 9.5% Stake in CAR-T Cell CDMO MedTherapy Biotechnology
核心洞察
Sudarshan Pharma Industries (搜索)' board approved acquiring 24,23,675.64 common shares of MedTherapy Biotechnology Inc. (搜索), representing a 9.50% stake in the company.
Promoters Hemal Mehta and Sachin Mehta will each acquire an additional 1.50% stake, bringing the total promoter-linked acquisition to 12.50%.
MedTherapy Biotechnology is a Boston-based cancer (搜索) cell and gene therapy company founded in 2018 as an integrated CAR-T Cell CDMO.
Sudarshan Pharma Industries (搜索) Limited has approved the acquisition of a 9.50% equity stake in MedTherapy Biotechnology Inc. (搜索), a Boston-based cancer (搜索) cell and gene therapy company, marking a strategic move into the CAR-T cell therapy manufacturing space. The board of directors approved the transaction at their meeting held on 5 September 2026.
Under the terms of the transaction, Sudarshan Pharma will acquire 24,23,675.64 equity shares of common stock, each with a par value of US$0.0001, of MedTherapy Biotechnology Inc. (搜索), a corporation incorporated under the laws of the State of Delaware. This holding is equivalent to 9.50% of the issued and outstanding share capital of the company.
In a parallel transaction, Hemal Mehta (Chairman & Managing Director) and Sachin Mehta (Joint Managing Director), promoters of Sudarshan Pharma, will each acquire 3,82,685.63 equity shares of common stock of MedTherapy Biotechnology Inc. (搜索), equivalent to 1.50% each of the issued and outstanding share capital. Combined with the company's 9.50% stake, the promoter-linked acquisitions bring the total to 12.50%.
MedTherapy Biotechnology: An Integrated CAR-T Cell CDMO
MedTherapy Biotechnology is a Boston-based global cancer (搜索) cell and gene therapy company founded in 2018 by experts from Harvard and former Novartis executives. The company operates as an end-to-end, integrated CAR-T Cell CDMO (contract development and manufacturing organization), with a commercial-scale GMP manufacturing facility in New Delhi, India, and a technology development site in Boston, USA.
The company was founded by experts in the cancer (搜索) field with a stated mission to make CAR-T cell treatment "so affordable and accessible that almost every cancer patient would be able to afford it." This focus on affordability and accessibility positions MedTherapy Biotechnology within the broader effort to expand patient access to cell and gene therapies.
Strategic Significance
The acquisition aligns Sudarshan Pharma with a company positioned at the intersection of cell therapy innovation and manufacturing scale. MedTherapy Biotechnology's integrated CDMO model—spanning technology development in Boston and commercial-scale GMP manufacturing in New Delhi—reflects a dual-continent operational footprint designed to support the production of CAR-T cell therapies.
The transaction underscores growing interest in CAR-T cell therapy manufacturing capacity as the field advances, with MedTherapy Biotechnology's end-to-end integrated approach offering a potential pathway to reduce costs and broaden access to these advanced cancer (搜索) treatments.